That's it. Two people in one of the dosing groups got a rash at the subcutaneous injection site. This was the straw that broke the camel's back for a company in dire shape. What should have been a slight, temporary setback resulted in the entire trial being permanently shut down. No question about it- it was definitely more of a failure of management than it was a failure of the drug.
Occam's razor:the simplest solution is most likely the right one.
Hanlon's razor:never attribute to malice that which is adequately explained by stupidity.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.